Electronic supplementary material [ESM]

Title: Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study

Journal Name: Pediatric Drugs

Authors: Nina Magnolo, MD[1], Külli Kingo, MD, PhD [2], Vivian Laquer, MD[3], John Browning, MD[4], Adam Reich MD, PhD[5], Jacek C. Szepietowski, MD, PhD, FRCP (Edin)[6], Deborah Keefe, MD, MPH[7], Philemon Papanastasiou[8], Weibin Bao, MS[7], Pascal Forrer, PhD[8], Manmath Patekar, MD[8]

Author Affiliations: [1]University Hospital Münster, Münster, Germany; [2]Tartu University Hospital and University of Tartu, Tartu, Estonia; [3]First OC Dermatology, Fountain Valley, California, USA; [4]University of Texas Health Science Center San Antonio, San Antonio, Texas, USA; [5]Department of Dermatology, Institute of Medical Science, Medical College of Rzeszów University, Rzeszów, Poland; [6] Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland; [7]Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; [8]Novartis Pharma AG, Basel, Switzerland

Corresponding author:

Nina Magnolo, MD,

University Hospital Münster,

Münster, 48149, Germany.

Email:Nina.Magnolo@ukmuenster.de

Supplemental Figure 1. Study Design up to Week 52



*Maximum 4 weeks. ☆ Randomization ↓ Active dose administration, including every 4 weeks from week 52 to week 204.
LD, low dose; HD, high dose; N, number of patients

Supplemental Table 1. Baseline Characteristics of Participants

Characteristics (All patients randomized)	Low dose secukinumab (N=42)	High dose secukinumab (N=42)	Secukinumab total (N=84)
Age group, n (%)			
6 to <12 years	17 (40.5)	16 (38.1)	33 (39.3)
12 to <18 years	25 (59.5)	26 (61.9)	51 (60.7)
Female, n (%)	20 (47.6)	25 (59.5)	45 (53.6)
Caucasian, n (%)	39 (92.9)	38 (90.5)	77 (91.7)
Weight strata, n (%)			
<25 kg	4 (9.5)	4 (9.5)	8 (9.5)
25 to <50 kg	13 (31.0)	12 (28.6)	25 (29.8)
≥50 kg	25 (59.5)	26 (61.9)	51 (60.7)
BMI (kg/m^2), mean (SD)	21.7 (5.2)	22.2 (4.5)	21.9 (4.8)
Disease severity strata[a] (as per randomization), n (%)			
Moderate	30 (71.4)	31 (73.8)	61 (72.6)
Severe	12 (28.6)	11 (26.2)	23 (27.4)
Baseline IGA score, n (%)			
3=Moderate disease	29 (69.0)	29 (69.0)	58 (69.0)
4=Severe disease	13 (31.0)	13 (31.0)	26 (31.0)
PASI, mean (SD), at baseline	18.5 (5.2)	19.3 (6.7)	18.9 (6.0)
CDLQI total score, mean (SD), at baseline	10.6 (6.0)	13.0 (7.0)	–

[a]Disease severity strata: moderate=PASI score 12 to <20 and IGA mod 2011 score 3/4 or PASI score ≥20 and IGA mod 2011 score 3 and severe=PASI score ≥20 and IGA mod 2011score 4

BMI, body mass index; CDLQI, Children's Dermatology Life Quality Index; IGA mod2011, Investigator's Global Assessment modified 2011; N, total number of patients; n, number of patients; PASI, Psoriasis Area and Severity Index; SD, standard deviation

Supplemental Figure 2. IGA mod 2011 and PASI Responses (Weeks 0–52) (Analyses by Age and Dose Groups)

S2.A Low Dose Secukinumab (6–<12 years); (N=17)



S2.B High Dose Secukinumab (6–<12 years); (N=16)



S2.C Low Dose Secukinumab (12–<18 years); (N=25)



S2.D High Dose Secukinumab (12–<18 years); (N=26)



IGA 0/1, Investigator's Global Assessment 0/1; N, total number of patients; PASI, Psoriasis Area and Severity Index

Supplemental Figure 3. IGA 0/1 and PASI Responses (Weeks 0–52) (Analyses by Baseline Body Weight and Dose Groups)[a]

S3.A Secukinumab 75 mg (<25 kg); (N=8)



S3.B Secukinumab 75 mg (25–<50 kg); (N=13)



S3.C Secukinumab 150 mg (25–<50 kg); (N=12)



S3.D Secukinumab 150 mg (≥50 kg); (N=25)



S3.E Secukinumab 300 mg (≥50 kg); (N=26)



[a]Body weight and dose group (secukinumab 75 mg [LD] and <25 kg, secukinumab 75 mg [LD] and 25 to <50 kg, secukinumab 150 mg [HD] and 25 to <50 kg, secukinumab 150 mg [HD] and ≥50 kg; secukinumab 300 mg and ≥50kg)
Note: There were no patients in ≥50 kg group for secukinumab 75 mg, <25 kg group for secukinumab 150 mg and 25 kg and ≥25 to <50 kg group for secukinumab 300 mg
IGA 0/1, Investigator's Global Assessment 0/1; N, total number of patients; PASI, PsoriasisArea and Severity Index

Supplemental Figure 4. IGA 0/1 and PASI Responses (Weeks 0–52) (Analyses by Baseline Disease Severity and Dose Groups)

S4.A Low Dose Secukinumab (Moderate); (N=30)



S4.B High Dose Secukinumab (Moderate); (N=31)



S4.C Low Dose Secukinumab (Severe); (N=12)



S4.D High Dose Secukinumab (Severe); (N=11)



IGA 0/1, Investigator's Global Assessment 0/1; N, total number of patients; PASI, Psoriasis Area and Severity Index